Eximis Surgical

Eximis Surgical, Inc. is a medical device company developing the Eximis Laparoscopic Specimen Removal System, a platform intended to let surgeons remove large tissue specimens through the small incisions used in minimally invasive procedures rather than requiring a larger incision at the end of the operation. The company frames the problem as a persisting gap in laparoscopic, thoracoscopic and robotic surgery: incisions and ports are small, but specimen extraction can force surgeons to enlarge an incision.

The system is designed to keep the specimen fully contained during segmentation and removal to minimize tissue leakage, to work within already clinically adopted specimen-bag workflows, to make segmentation and removal more efficient, to produce regular, clean-cut segments suitable for pathologic assessment, and to keep incision sizes consistent with standard and single-incision laparoscopic procedures. The platform uses multiple integrated containment bags and a cutting approach that removes the need for sharps during segmentation.

As of the most recent sourced description, the company is pre-market and working toward an FDA submission for the first device on the platform. Proceeds from its Series B were designated for U.S. regulatory activities and, per earlier coverage, regulatory approval and commercial launch of the system.

Founding story

Founded in 2014. Co-founders include Kristin Johnson, who served as CEO at the time of the 2018 financing, and Donna Ford-Serbu, identified as co-founder and CEO at the time of the Series B; William Gregg is also identified as a co-founder.

Business model

Pre-revenue, pre-market medical device developer funded by venture capital and strategic corporate investment, intending to bring a laparoscopic specimen removal system to market.

Traction

The company reports being in the pre-market phase and actively working toward FDA submission for its first platform device. Development of the solution had been underway for more than five years as of the Series B announcement. Reported headcount is in the 11-20 range.

Latest developments

Olympus Innovation Ventures announced participation in Eximis Surgical's $8.7 million Series B round, with proceeds directed to U.S. regulatory activities for the Eximis Laparoscopic Specimen Removal System; the company describes itself as working toward FDA submission for its first device.